Objective: Accurate identification of the earliest cognitive changes associated with Alzheimer's disease (AD) is critically needed. Item-level information within tests of category fluency, such as lexical frequency, harbors valuable information about the integrity of semantic networks affected early in AD.To determine the potential of lexical frequency as a cognitive marker of AD risk, we investigated whether lexical frequency of animal fluency output differentiated APOE ε4 carriers from noncarriers in a cross-sectional design among older African-American adults without dementia. Method: We analyzed animal fluency performance using mean number of items and mean lexical frequency among 230 cognitively normal African Americans with and without the APOE ε4 allele. Results: Lexical frequency was higher in APOE ε4 carriers than noncarriers when analyzed as a mean score and within time bins. In contrast, we found no group difference in the number of items produced. Lexical frequency was particularly sensitive to ε4 status after the first 10 s of the 60-s animal fluency task. Conclusion: Our results suggest that psycholinguistic features may hold value as a cognitive biomarker for identifying people at high risk of AD. General Scientific SummaryDecline in cognition occurs years before the symptoms are distinct enough to establish a clinical diagnosis of Alzheimer's disease (AD) based on traditional neuropsychological test scores. We showed that an alternative, psycholinguistic score of the category fluency task could predict AD genetic risk (having the APOE ε4 allele) in older adults whose overall cognition and function are within normal limits. These results suggest that psycholinguistic features may hold value as a cognitive biomarker for identifying people at high risk of AD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.